- At this time, CDC recommends that people not consume kratom in any form because it could be contaminated with Salmonella.
- CDC’s recommendation may change as more information becomes available.
- Kratom is also known as Thang, Kakuam, Thom, Ketom, and Biak.
- Kratom(https://www.cdc.gov/mmwr/volumes/65/wr/mm6529a4.htm) is a plant consumed for its stimulant effects and as an opioid substitute.
- CDC, public health and regulatory officials in several states, and the U.S. Food and Drug Administration are investigating a multistate outbreak of Salmonella I 4,,12:b:- infections.
- Epidemiologic evidence(https://www.cdc.gov/foodsafety/outbreaks/investigating-outbreaks/index.html) indicates that kratom is a likely source of this multistate outbreak.
- Ill people in this outbreak report consuming kratom in pills, powder, or tea.
- No common brands or suppliers of kratom products have been identified at this time.
- Because no common source of Salmonella-contaminated kratom has been identified, CDC is recommending against consuming any kratom.
- Twenty-eight people infected with the outbreak strain of Salmonella I 4,,12:b:- have been reported from 20 states.
- Eleven hospitalizations have been reported.
- No deaths have been reported.
- This investigation is ongoing. CDC will provide updates when more information is available.
- The U.S. Food and Drug Administration is warning consumers not to use Mitragyna speciosa, commonly known as kratom, a plant which grows naturally in Thailand, Malaysia, Indonesia, and Papua New Guinea. FDA is concerned that kratom, which affects the same opioid brain receptors as morphine, appears to have properties that expose users to the risks of addiction, abuse, and dependence.
There are no FDA-approved uses for kratom, and the agency has received concerning reports about the safety of kratom. FDA is actively evaluating all available scientific information on this issue and continues to warn consumers not to use any products labeled as containing the botanical substance kratom or its psychoactive compounds, mitragynine and 7-hydroxymitragynine. FDA encourages more research to better understand kratom’s safety profile, including the use of kratom combined with other drugs.
Since identifying kratom on an import alert for unapproved drugs in 2012 and on a second import alert in February 2014 regarding kratom-containing dietary supplements and bulk dietary ingredients, FDA has taken a number of additional actions, including:
- In September 2014, U.S. Marshals, at the FDA’s request, seized more than 25,000 pounds of raw kratom material worth more than $5 million from Rosefield Management, Inc. in Van Nuys, California.
- In January 2016, U.S. Marshals, at the FDA’s request, seized nearly 90,000 bottles of dietary supplements labeled as containing kratom and worth more than $400,000. The product, manufactured for and held by Dordoniz Natural Products LLC, located in South Beloit, Illinois, is marketed under the brand name RelaKzpro.
- In August 2016, U.S. Marshals, at the FDA’s request, seized more than 100 cases of products labeled as containing kratom and worth more than $150,000. The products are distributed by Nature Therapeutics LLC, which does business as Kratom Therapy and is located in Grover Beach, California. The seized products are marketed under the brand name Kratom Therapy.
While FDA evaluates the available safety information about the effects of kratom, the agency encourages health care professionals and consumers to report any adverse reactions to the FDA’s MedWatch program: